TuHURA Biosciences, Inc. (HURA): Total Liabilities
$6.42M
As of 2025-12-31
$13.25M
As of 2026-06-30
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $6.42M | +19.5% | 2026-03-31, Balance as of period end |
| 2024-12-31 | $5.37M | n/a | 2026-03-31, Balance as of period end |
| 2024-06-30 | $2.44M | n/a | 2024-10-07, Balance as of period end |
| 2023-12-31 | $5.92M | n/a | 2025-03-31, Balance as of period end |
| 2023-06-30 | $3.25M | -21.8% | 2024-10-07, Balance as of period end |
| 2022-06-30 | $4.15M | +40.2% | 2023-09-18, Balance as of period end |
| 2021-06-30 | $2.96M | +10.7% | 2022-09-27, Balance as of period end |
| 2020-06-30 | $2.67M | +29.2% | 2021-09-28, Balance as of period end |
| 2019-06-30 | $2.07M | +26.2% | 2020-09-18, Balance as of period end |
| 2018-06-30 | $1.64M | +23.0% | 2019-09-09, Balance as of period end |
| 2017-06-30 | $1.33M | -11.0% | 2018-09-24, Balance as of period end |
| 2016-06-30 | $1.50M | -55.9% | 2017-09-27, Balance as of period end |
| 2015-06-30 | $3.40M | -42.5% | 2016-09-13, Balance as of period end |
| 2014-06-30 | $5.91M | n/c | 2015-11-16, Balance as of period end |
| 2013-12-31 | $5.14M | +240.0% | 2014-08-28, Balance as of period end |
| 2012-12-31 | $1.51M | n/a | 2014-08-28, Balance as of period end |
| 2012-06-30 | $10.0K | n/a | 2012-12-20, Balance as of period end |
| 2011-06-30 | $0 | n/a | 2012-12-20, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| TuHURA Biosciences, Inc. (HURA) | 2025-12-31 | $6.42M | +19.5% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $71.53B | -6.1% |
| TherapeuticsMD, Inc. (TXMD) | 2025-12-31 | $10.78M | -5.9% |
| Pfizer Inc (PFE) | 2025-12-31 | $121.39B | -2.8% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $117.67B | +8.3% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $99.59M | +24.7% |
| Provectus Biopharmaceuticals, Inc. (PVCT) | 2025-12-31 | $7.00M | +0.4% |
| Lisata Therapeutics, Inc. (LSTA) | 2025-12-31 | $3.14M | -44.7% |
| Heron Therapeutics, Inc. (HRTX) | 2025-12-31 | $241.54M | -9.5% |
Compare HURA, BMY, TXMD, PFE side by side · Screen every company in Pharmaceutical Preparations ↗